SS
BDRX

SBI Securities’s Biodexa Pharmaceuticals BDRX Stock Holding History

SBI Securities’s Portfolio BDRX Stock Details BDRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84 Sell
29
-1
-3% -$3 ﹤0.01% 3546
2026
Q1 		$93 Buy
30
+10
+50% +$70 ﹤0.01% 3423
2025
Q4 		$229 Sell
20
-3
-13% -$85 ﹤0.01% 3168
2025
Q3 		$765 Sell
23
-90
-80% -$3.23K ﹤0.01% 2804
2025
Q2 		$4.9K Buy
+113
New +$7.2K ﹤0.01% 1993
2025
Q1 		– Hold
0
– – – 4108
2024
Q4 		– Hold
0
– – – 4005

Other funds holding BDRX

GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
APW
Allied Private Wealth Boca Raton, Florida $156M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
HHCP
Hilton Head Capital Partners Hilton Head Island, South Carolina $198M AUM
CIAM
Caitong International Asset Management Hong Kong $729M AUM 1,176.98% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return

SBI Securities's BDRX Position: Q2 2026 in Review

SBI Securities reduced its Biodexa Pharmaceuticals (BDRX) stake by 3.3% in Q2 2026, selling an estimated $3 and leaving 29 shares worth $84. The position accounts for ﹤0.01% of the portfolio, ranked #3546.

SBI Securities first reported a position in BDRX in Q2 2025 and has held it in 5 quarters since. The position peaked at $4.9K in Q2 2025. 7 funds tracked by Wall St. Rank hold BDRX as of Q2 2026.

  • SBI Securities held 29 shares of Biodexa Pharmaceuticals worth $84 as of Q2 2026.
  • SBI Securities sold 1 Biodexa Pharmaceuticals share in Q2 2026, an estimated $3.
  • Biodexa Pharmaceuticals made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #3546 holding.
  • SBI Securities first reported a position in Biodexa Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • SBI Securities's Biodexa Pharmaceuticals position peaked at $4.9K in Q2 2025.
  • 7 funds tracked by Wall St. Rank held Biodexa Pharmaceuticals as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.